Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: Epilepsy Behav. 2020 Jan 27;104(Pt A):106907. doi: 10.1016/j.yebeh.2020.106907

Table 4:

Multivariable analysis: Research screening participation by patient characteristics among those with epilepsy

Unadjusted Results Final Multivariable Model N=170
Variable Odds Ratio* 95% Confidence Interval P-value Odds Ratio* 95% Confidence Interval P-value
Epilepsy type 0.10 0.08
 Generalized versus focal 2.57 0.84–7.89 0.10 3.30 1.02–10.66 0.05
 Unknown versus focal 4.75 0.60–37.85 0.14 3.62 0.44–29.94 0.23
Depression score** 1.13 1.03–1.25 0.008 1.13 1.01–1.26 0.03
Current antidepressant therapy*** 2.61 1.26–5.43 0.01 2.37 1.04–5.41 0.04
*

Odds of opting-in to research screening

**

Odds per one-point increase in score on the NDDI-E

***

SSRI, SNRI, mirtazapine, bupropion, or buspirone